# A Phase 2 Study to Evaluate the Cardiac and Renal Effects of Short Term Treatment With Elamipretide in Patients Hospitalized With Congestion Due to Heart Failure

Study · id `cardio:ct-nct02914665` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02914665](<https://clinicaltrials.gov/study/NCT02914665>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02914665

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 308 participants.

## Technical summary

Registry record NCT02914665. Randomized; quadruple masking; primary purpose treatment. Start 2016-10-20 (actual); primary completion 2017-11-27 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 308 participants (enrolled count; ClinicalTrials.gov record NCT02914665, source copy `cardio:ctgov-nct02914665-2020-07-28`, retrieved 2026-10-26)
- Started: 2016-10-20 (actual) (ClinicalTrials.gov record NCT02914665, source copy `cardio:ctgov-nct02914665-2020-07-28`, retrieved 2026-10-26)
- Primary completion: 2017-11-27 (actual) (ClinicalTrials.gov record NCT02914665, source copy `cardio:ctgov-nct02914665-2020-07-28`, retrieved 2026-10-26)
- Completion: 2017-11-27 (actual) (ClinicalTrials.gov record NCT02914665, source copy `cardio:ctgov-nct02914665-2020-07-28`, retrieved 2026-10-26)
- Countries: Belgium; Bulgaria; France; Hungary; Latvia; Netherlands; Poland; Serbia; Spain; United Kingdom (ClinicalTrials.gov record NCT02914665, source copy `cardio:ctgov-nct02914665-2020-07-28`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02914665-2020-07-28`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Phase 2 Study to Evaluate the Cardiac and Renal Effects of Short Term Treatment With Elamipretide in Patients Hospitalized With Congestion Due to Heart Failure
- Condition: Heart Failure
- Intervention (Drug): elamipretide
- Intervention (Drug): Placebo
- Lead sponsor: Stealth BioTherapeutics Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)

## Provenance

Content hash: 651293855fc78e4da969be0ed81edadd0ae6e6b371212faa9498cdfa1cfd0699
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
